Sorrento Therapeutics, Inc. - Common Stock (SRNE)
$0.0005
0.00 (0.00%)
SRNE Stock Quote Delayed 30 Minutes
Sorrento Therapeutics Fails the Test as a Covid-19 Value Play
Lack of a track record, a lagging Covid-19 test project and executive turmoil make SRNE stock a coronavirus play to avoid.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
19,707
Day's Range
$0.0002 - $0.0005
52-Week Range
$0.0001 - $0.09
Dividend & Yield
N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therapeutics, Inc. - Common Stock News
Sorrento Therapeutics Is a Scary, Risky Potential Buy
Sorrento Therapeutics has lost 44% since firing its chief financial officer on Aug. 19. Is SRNE stock a buy given its drop in recent days?
Stay Away From Sorrento Therapeutics Here
Sorrento Therapeutics looks overvalued here. Investors in SRNE stock can expect dilution from equity/debt raises, given the company's ongoing burn rate and deals.
Understand the Science Before Deciding on Sorrento Therapeutics
SRNE stock was one of the top performers of this year. But just as quickly, shares have faded, and I'm not sure its Covid-19 pipeline will pan out.
Don’t Discount the Bears On Sorrento Stock
SRNE stock has been the target of a so-called "bear raid." But shorts make good points, and red flags remain for Sorrento.
Sorrento Therapeutics Stock Is Down but Not Out
SRNE stock is 60% off its highs, but such is the nature of these stocks. They are always one headline away from greatness.
Sorrento Is Only for Thrill Seekers, But the Payoff Could Be Huge
If some of its Covid-19 pipeline hits it big, SRNE stock will reward your faith handsomely -- but it's a big 'if.'
Sorrento’s Covid-19 Test, Acquisitions Should Help SRNE Stock Surge
Sorrento's COVID-19 test appears to be superior to competing diagnostics, and it just made a good acquisition, while its overall strategy is sound.
Why Sorrento Has Turned Into a Bitter Battleground Stock
Sorrento Therapeutics is in a massive war of words with short sellers such as Hindenburg Research. And for now, SRNE stock bears are winning.
Sorrento Is Stuck In a Story of Its Own Creation
SRNE stock is up over 230% as speculative investors buy the hope that one of its three Covid-19 approaches will latch on. But what if none of them do?
The Bull Case for Sorrento Therapeutics Is Exceptionally Thin at This Stage
SRNE stock has a lot of potential but with the clinical prematurity of its product base it's difficult to invest in Sorrento at this time.
Sorrento Therapeutics Stock Is a Solid Coronavirus Pick
While SRNE stock is likely to be volatile in the near term, the firm's diagnostic tests look like some of the best options on the market making it a good coronavirus play
Sorrento Is Only Worth Investor Dollars if You Believe This
SRNE stock has jumped on Covid-19 vaccine cure hopes. But even if that doesn't pan out, Sorrento could still find gold.
Sorrento Stock: Gambling on Coronavirus
Few companies are in all the major Covid-19 sectors, but Sorrento has made claims for a test, a vaccine and a cure. This brought many eyes to SRNE stock.
The Next Bull Run Will Be Harder For Sorrento Therapeutics
Jim Cramer recently called out the markets for not recognizing the potential of Sorrento Therapeutics and SRNE stock. Is he right?
3 Key Questions to Answer Before Buying Sorrento Therapeutics Stock
From relative obscurity to generated headlines, SRNE stock has jumped on big claims by Sorrento Therapeutics. You should think carefully about these three questions before placing a bet.
Vision of a Covid-19 Breakthrough Makes Sorrento Therapeutics Stock a Buy
SRNE stock is an underappreciated gem as the company's recent acquisition offers significant product-pipeline expansion.
Speculative Investors Should Buy Sorrento Stock
Sorrento's drugs could generate a few billion dollars of revenue by the end of 2021, making SRNE stock attractive for speculative investors.
